Introduction
============

It is increasingly common and necessary to conduct multicenter, population-based studies with data from a large number of geographically and demographically diverse individuals.[@b1-clep-10-1773]--[@b6-clep-10-1773] However, it is not always possible or desirable to share deidentified individual-level data sets in multicenter studies. For example, some data partners may be concerned about potential breaches of patient privacy, while others may be worried about unauthorized uses of their data, incorrect analysis or interpretation of the data, or inadvertent disclosures of sensitive corporate or institutional information.[@b7-clep-10-1773]--[@b10-clep-10-1773] Certain health plans or delivery systems, which collect electronic health data as part of clinical care, have contractual agreements with their patients that restrict sharing of individual-level data for purposes other than patient care. Even when patients, health plans, and delivery systems are amenable to sharing individual-level data, sometimes the time and resources required to formalize data-sharing agreements can significantly delay a research project or make it infeasible.

There have been ongoing efforts to develop and apply more privacy-protecting analytic and data-sharing methods that do not require transferring of individual-level data sets in multicenter studies. For example, methods that leverage summary scores (eg, propensity scores and disease risk scores) are appealing because they allow researchers to adjust for a large number of covariates without having to share highly granular information.[@b11-clep-10-1773]--[@b13-clep-10-1773] Prior studies have demonstrated the feasibility and validity of using only summary-level information from participating sites to perform matched or stratified analysis with summary scores for fixed exposures and onetime binary and time-to-event outcomes.[@b12-clep-10-1773]--[@b14-clep-10-1773] Meta-analysis of site-specific effect estimates has also been shown to be a viable analytic option in certain multicenter studies.[@b13-clep-10-1773]--[@b15-clep-10-1773] Distributed regression, which has theoretical advantages of being computationally equivalent to pooled individual-level data regression,[@b16-clep-10-1773],[@b17-clep-10-1773] has also been used in some multicenter studies.[@b18-clep-10-1773]--[@b21-clep-10-1773]

There is a continued need for more methodological development and empirical assessment of these more privacy-protecting analytic methods in real-world multicenter studies. We performed a study to empirically assess the feasibility and validity of 1) conducting distributed linear regression analysis in a large national distributed data network; and 2) combining distributed regression with propensity scores, a data dimension reduction technique, to achieve more privacy protection and analytic flexibility.

Materials and methods
=====================

Setting
-------

The National Patient-Centered Clinical Research Network (PCORnet) is a distributed data network designed to support studies that address questions important to patients and other stakeholders.[@b22-clep-10-1773] It includes 13 Clinical Data Research Networks (CDRNs), 20 People-Powered Research Networks, two Health Plan Research Networks, and a coordinating center. The CDRNs, each of which includes multiple participating health systems, provide access to electronic health record (EHR) or administrative claims data from more than 100 million individuals and over 40 million patients who could be recruited into pragmatic clinical trials. PCORnet employs a common data model to standardize the data extracted from the EHRs or administrative claims of the participating health systems.[@b23-clep-10-1773] The data domains extracted from the EHRs included patient demographics, diagnoses and procedures, vital signs, and laboratory test results.

Study cohort
------------

The PCORnet Bariatric Study was initiated in 2016 to evaluate the comparative effectiveness and safety of three commonly performed bariatric procedures -- adjustable gastric band, Roux-en-Y gastric bypass, and sleeve gastrectomy.[@b24-clep-10-1773] The study identified patients who underwent a primary bar-iatric procedure in participating health systems from January 1, 2005, to September 30, 2015. Patients must meet the following criteria to be eligible for the study: 1) aged 21--79 years at the index procedure; 2) body mass index ≥35 kg/m^2^ in the year before their procedure; 3) no multiple conflicting bariatric procedure codes on the same day; 4) no revision bariatric procedure code, gastrointestinal cancer diagnosis code, or fundoplasty procedure in the year before the index procedure; 5) no emergency room encounter on the day of index procedure; and 6) a weight measurement 6--18 months after the index procedure. A full description of the design and findings from the weight loss study are available elsewhere.[@b25-clep-10-1773]

Exposure
--------

We restricted the analysis to the comparison of Roux-en-Y gastric bypass and sleeve gastrectomy.

Outcome
-------

The outcome of interest was percent total weight loss at 1 year after surgery in comparison with presurgery weight, calculated as \[(postsurgery weight at 1 year − baseline weight)/baseline weight\] and modeled as a continuous variable.

Confounders
-----------

We included the same potential confounders identified a priori by the study investigators in the main weight loss analysis based on their subject matter knowledge and input from stakeholders. These confounders included age; sex; race; Hispanic ethnicity; year of procedure; site; combined comorbidity score;[@b26-clep-10-1773] baseline weight; the number of days between baseline weight measurement and the index procedure; baseline smoking status; total days of hospitalization in the year prior to surgery; and diagnosis of anxiety, deep vein thrombosis, depression, diabetes, dyslipidemia, eating disorder, gastroesophageal reflux disease, hypertension, infertility, kidney disease, nonalcoholic fatty liver disease, osteoarthritis, polycystic ovarian syndrome, psychosis, pulmonary embolism, sleep apnea, and substance use disorder, recorded in the year prior to surgery. As described in more detail below, these confounders were accounted for in the outcome regression model as individual covariates, propensity scores, or both.

Pooled individual-level data analysis
-------------------------------------

We used the pooled deidentified individual-level ordinary least squares regression analysis as the reference analysis. For this analysis, we wrote distributed programs to run at each site to pull individual-level data and then combined all site-specific individual-level data sets together to form a standard pooled deidentified analysis data set, which included exposure status, all confounders, site indicators, and the outcome. To estimate propensity scores within the combined data set, we fit a logistic regression model, separately for each site, which predicted the probability of receiving Roux-en-Y gastric bypass procedure (vs sleeve gastrectomy) using all the confounders described above as predictors.

We fit three ordinary least squares linear regression models to examine the difference in percent total weight loss at 1 year compared with baseline, comparing the Roux-en-Y gastric bypass procedure with the sleeve gastrectomy procedure. Model 1 included an exposure indicator variable, indicator variables for sites, and potential confounders as individual variables. The purpose of this analysis was to demonstrate the feasibility and empirical validity of conducting multivariable-adjusted distributed linear regression in large real-world distributed data networks such as PCORnet. Model 2 included the exposure and site indicator variables and propensity scores (in deciles, defined within each site). The purpose of this analysis was to examine the feasibility and empirical validity of combining distributed regression with propensity scores via modeling. Model 3 included the exposure and site indicator variables, potential confounders as individual variables, and propensity scores (in deciles). This model is an example of a "doubly robust" regression model -- the results would be valid if either the propensity score model or the outcome model was correctly specified.[@b27-clep-10-1773],[@b28-clep-10-1773]

Distributed linear regression
-----------------------------

Distributed regression is a suite of methods that enable researchers to conduct multidatabase regression analysis without the need to centrally combine all individual-level data from participating sites.[@b16-clep-10-1773],[@b17-clep-10-1773] As shown in [Figure 1](#f1-clep-10-1773){ref-type="fig"}, it performs the same numeric algorithm as standard regression that is based on individual-level data but uses only summary statistics for computation. By following the same computation process, distributed regression and pooled individual-level data analysis should theoretically produce statistically equivalent results.

For distributed linear regression, the total sums of squares and cross products (SSCP) matrix for the intercept, dependent variable, and independent variables across all databases is sufficient to obtain the overall parameter estimates and associated covariance matrix. Because of its statistical properties, the total SSCP matrix can be obtained by simply summing up the site-specific SSCP matrices across all databases. In other words, we can request the summary-level SSCP matrix from each participating site and combine these matrices centrally to produce the parameter estimates and SEs (or 95% CIs), as shown in [Figure 2](#f2-clep-10-1773){ref-type="fig"}. Although standard statistical software packages cannot readily perform distributed linear regression, they can produce the SSCP matrix. For example, SAS software has the procedure PROC REG, which performs linear regression analysis, and it readily inputs and outputs SSCP matrix.

To perform distributed linear regression, we followed a process similar to the one described in the pooled individual-level data analysis, but with more computation done at the site. [Figure 3](#f3-clep-10-1773){ref-type="fig"} describes the steps involved in each analysis. Specifically, we modified the distributed program used to pull individual-level data by including additional code that 1) fit a site-specific propensity score model and 2) decomposed the individual-level data into three sets of SSCP matrices, one for each regression model described above. We distributed the modified program to the participating sites for local execution. We then combined these individual site-specific SSCP matrices to produce parameter estimates and SEs.

The distributed SAS packages used to create the site-specific deidentified individual-level data sets (for the reference analysis) and SSCP matrices (for the distributed regression analysis) as well as the SAS programs used by the analysis center to produce the final results are publicly available on GitHub at <https://github.com/pcornet-analytics/bariatric>.

Comparison
----------

We compared the parameter estimate and standard error (SE) of each variable in each model (Models 1--3) from the pooled individual-level data analysis and distributed regression approach.

Secondary analysis
------------------

Due to small sample sizes, we expected some sites to have issues fitting their site-specific propensity score models. Therefore, we reran the analyses excluding sites that had any warnings or errors in their returned SAS logs.

Results
=======

We identified 43,110 eligible patients -- 23,963 underwent the Roux-en-Y gastric bypass procedure, and 19,147 patients had the sleeve gastrectomy procedure -- from 36 participating data marts. The sample size ranged from 5 to 16,257 across sites. [Table 1](#t1-clep-10-1773){ref-type="table"} summarizes the baseline characteristics of the study cohort by treatment group.

Analyses that included all sites, regardless of warnings or errors when fitting the site-specific propensity score models
-------------------------------------------------------------------------------------------------------------------------

For each of the three regression models, the results were identical between the distributed regression analysis and the corresponding pooled individual-level data analysis, as shown in [Tables 2](#t2-clep-10-1773){ref-type="table"}[](#t3-clep-10-1773){ref-type="table"}--[4](#t4-clep-10-1773){ref-type="table"}. Overall, the results showed that Roux-en-Y gastric bypass was associated with greater percent total weight loss than sleeve gastrectomy at 1-year follow-up -- approximately 5 percentage points greater in all the three regression models examined. The maximum difference in numerical value was 3.28×10^−11^ for the parameter estimate and SE across all the variables in Model 1, 3.24×10^−11^ in Model 2, and 3.29×10^−11^ in Model 3. Across regression models, adjusting for potential confounders as individual covariates, propensity scores, or both in the models produced similar effect estimates for the comparison of interest.

Analyses that included only sites without any warnings or errors when fitting the site-specific propensity score models
-----------------------------------------------------------------------------------------------------------------------

In total, 17 sites successfully executed the SAS package without any warnings or errors in the site-specific propensity score model. There were 36,476 patients -- 20,260 Roux-en-Y gastric bypass patients and 16,216 sleeve gastrectomy patients in these 17 sites. The sample size ranged from 242 to 16,257 across these sites. [Table S1](https://www.dovepress.com/get_supplementary_file.php?f=178163.pdf) summarizes the baseline characteristics of these patients by treatment group. For each of the three regression models, the results were identical between the pooled individual-level data analysis and the distributed regression analysis, as shown in [Tables S2--S4](https://www.dovepress.com/get_supplementary_file.php?f=178163.pdf). The maximum difference in numerical value was 3.91×10^−11^ for the parameter estimate and SE across all the variables in Model 1, 3.35×10^−11^ in Model 2, and 3.67×10^−11^ in Model 3. Across the regression models, adjusting for potential confounders as individual covariates, propensity scores, or both in the models produced similar effect estimates for the comparison of interest. Not surprisingly, the results from the 17 error-free sites, which comprised 85% (36,476 of 43,110) of the data, were similar to the results obtained from the corresponding analyses that included all data.

Discussion
==========

In this study, we demonstrated the feasibility of implementing distributed linear regression in an active, real-world, national distributed data network and the validity of this analytic method in producing results identical to those obtained from conventional pooled individual-level data analysis for a single continuous outcome. Although some of the prior studies have compared the results from distributed regression with those obtained from the corresponding pooled individual-level data analysis,[@b18-clep-10-1773]--[@b20-clep-10-1773] they were conducted within smaller distributed data networks or more controlled environments (ie, virtual or simulated distributed data networks). The current study is the largest study that demonstrated the feasibility and empirical validity of distributed regression. As these more privacy-protecting methods may be less well understood by researchers, empirical demonstration of their validity is essential for encouraging their adoption in practice.

To our knowledge, this is also the first study that combined distributed regression with propensity scores to provide even more privacy protection and analytic flexibility than either approach alone. Specifically, the approach first condenses information from a large number of covariates into a single measure and then further processes the condensed individual-level information into highly summarized information.

Propensity scores are a data dimension reduction technique that can summarize a large number of individual covariates into a single, less identifiable scalar. Methods that leverage the property of propensity scores have been shown to produce results identical or highly comparable to those obtained from pooled individual-level data analysis.[@b12-clep-10-1773]--[@b14-clep-10-1773] However, existing propensity score-based approaches only support matched or stratified analysis when sharing summary-level information. In this study, we demonstrated the feasibility of adjusting for propensity scores via regression modeling using only summary-level information in a multicenter study. Existing distributed regression requires all participating sites to fit the same multivariable-adjusted regression model.[@b18-clep-10-1773]--[@b20-clep-10-1773] By combining distributed regression with propensity scores, researchers now have the ability to adjust for different sets of covariates via site-specific propensity score models (more below).

Transparency and reproducibility in distributed analysis
--------------------------------------------------------

Without direct access to all the individual-level data from participating sites, researchers are required to specify all the descriptive and inferential analyses a priori as part of the data request process. It is possible and advisable to inspect the data using summary-level information (eg, "[Table 1](#t1-clep-10-1773){ref-type="table"}" that describes the patient characteristics at each site) before finalizing the regression model. It is also recommended to include some sites that are able and willing to share individual-level data to test the analytic code before full distribution. As with pooled deidentified individual-level data analysis, it is feasible to fit multiple regression models as sensitivity or secondary analyses, as we did in this study. By being completely explicit about the analysis, the distributed analytic approach minimizes the risk of data dredging and selective reporting. In other words, although the analytic approach used in this study may initially appear opaque to readers who are less familiar with the approach, it is actually more transparent and reproducible.

Distributed regression for other generalized linear models
----------------------------------------------------------

Although we only examined distributed linear regression, it is possible to conduct multivariable-adjusted distributed analysis for other commonly used generalized linear models, including logistic, Poisson, and Cox proportional hazards model.[@b18-clep-10-1773]--[@b20-clep-10-1773],[@b29-clep-10-1773]--[@b32-clep-10-1773] Unlike linear regression, which can be completed in a single computation step, the computation process of other regression models requires multiple iterative steps. The iterative process involves exchanging intermediate statistics and interim parameter estimates between the analysis center and participating sites. Manual exchanges of this summary-level information can be too tedious and labor-intensive to be practical in actual multicenter studies. However, there are a number of statistical packages and standalone software that enable researchers to perform distributed regression and partially or fully automate the file transfer process.[@b19-clep-10-1773],[@b20-clep-10-1773],[@b31-clep-10-1773]--[@b33-clep-10-1773] We chose not to assess the operational performance (eg, runtime) of our distributed regression analysis because it is highly network-dependent. Some multicenter studies have better (or less ideal) technical infrastructure to allow distributed regression to be conducted more (or less) efficiently.

Site-specific propensity score models vs a "global" propensity score model
--------------------------------------------------------------------------

We fit site-specific propensity score models because propensity scores are sensitive to the prevalence of exposure in the population under study. As the prevalence of bariatric procedures might vary across databases due to differences in clinical practice and other factors, patients from two different sites might not be comparable even if they had the same propensity score value. In addition, a given covariate (eg, diabetes) may have different effects on the probability of receiving a specific bariatric procedure at different sites. Therefore, it is generally advisable to estimate propensity scores by site and perform the analysis accounting for data source, eg, match on propensity scores within site, stratify jointly on site-specific propensity scores and site, and include both propensity scores and site as regressors. However, it is not always possible to estimate propensity scores by site because some sites might be too small to accommodate a robust propensity score model. Indeed, the number of patients in some sites in the current study was too low to allow the conventional rule of requiring 7--10 "outcome events" (ie, exposed patients) per covariate in the propensity score model.[@b34-clep-10-1773],[@b35-clep-10-1773] In a distributed environment, researchers have the ability to inspect the log or other summary-level output (eg, a patient characteristic table) to assess the feasibility of fitting site-specific propensity score models.

An alternative is to fit one propensity score model that adjusted for the confounders, site, and additional interaction terms between confounders and site, which was done in the primary analysis for this study.[@b25-clep-10-1773] This allows sites that do not have sufficient data to fit site-specific propensity score models to contribute their data to the analysis, with an additional assumption that the global propensity score model is correctly specified. It is straightforward to fit such a model in the pooled individual-level data analysis. Although we did not do it here, in principle it would be possible to fit a global propensity score model using distributed logistic regression. This is a topic for future research.

Some sites may have additional confounder information that can be included in the study. For example, some participating health systems in this study may have dietary information from patients who underwent bariatric procedure. For simplicity, we only adjusted for confounders that were available in all participating sites. It is straightforward computationally to include different sets of confounders in the site-specific propensity score models, but the use of different confounders across sites would need to be justified scientifically. Future studies should examine the strengths and limitations of allowing site-specific confounder lists.

Limitations of distributed regression approach
----------------------------------------------

Although we were able to illustrate the statistical equivalence of the distributed linear regression approach to pooled individual-level data analysis for a one-time continuous outcome, we were not able to fully replicate the primary analysis in the main study, which used a linear mixed-effects model to simultaneously estimate the association between bariatric surgeries and percent total weight loss at 1, 3, and 5 years postsurgery.[@b25-clep-10-1773] In the main study, the estimated difference in percent weight loss at 1 year post-surgery was −5.9% comparing Roux-en-Y gastric bypass with sleeve gastrectomy. The results from the distributed linear regression analyses, which were between −5.3% and −5.5% across the three models, were comparable. We may have observed greater dissimilarities if we estimated a 3-or 5-year postsurgery difference where the advantages of using repeated measure analysis with a linear mixed-effects model are more pronounced due to missing data assumptions being relaxed (eg, mixed-effects models assume that data are missing at random borrowing from more outcomes being measured). Distributed regression has not been fully developed for models that examine repeated outcomes or repeated exposures.

In addition, certain model diagnostics cannot currently be performed with summary-level information. For example, creating residual plots to examine the normality assumption in linear regression requires sharing of individual-level data. It is possible to introduce noise to the individual-level data but doing so could impact its fidelity.[@b36-clep-10-1773] It is also more challenging to identify or assess idiosyncratic data issues at participating sites without direct access to all individual-level data being analyzed. Enhancing the capability of distributed regression to perform other tasks that can readily be performed with individual-level data is another topic for future research.

Other privacy-protecting analytic and data-sharing methods
----------------------------------------------------------

Prior studies have demonstrated the feasibility and validity of using summary-level risk-set data to perform propensity score-matched and propensity score-stratified analysis.[@b11-clep-10-1773]--[@b13-clep-10-1773] Recent work has explored the feasibility of conducting inverse probability-weighted analysis using risk-set data.[@b37-clep-10-1773] Our study shows the feasibility of adjusting for propensity scores via modeling using only summary-level information in multicenter studies. In addition to summary score-based methods and distributed regression, meta-analysis of site-specific estimates is another analytic option that does not require sharing of individual-level data in a multicenter study. Studies have shown that meta-analysis produced results comparable to those from pooled individual-level data analysis.[@b13-clep-10-1773]--[@b15-clep-10-1773],[@b38-clep-10-1773] However, unlike distributed regression, meta-analysis generally produces similar, but not identical, results to those from pooled individual-level data analysis.

Instead of using distributed regression, it would also be possible to request stratified counts of all unique combinations of the confounders from participating sites to fit a regression model in a multicenter study. The approach requires all confounders to be binary or categorical variables.[@b39-clep-10-1773] It would be feasible to employ that approach for Model 2, but not the other two models examined in the study because of the large number of confounders in these two models and because some of them were modeled as continuous variables.

Conclusion
==========

We demonstrated the feasibility and empirical validity of performing distributed linear regression analysis for one-time linear outcomes within a large distributed data network and the feasibility and validity of combining distributed regression and propensity scores to offer additional privacy protection and analytic flexibility. Along with other existing privacy-protecting analytic methods, distributed regression is a viable and valid analytic option that allows researchers to analyze data that may otherwise be inaccessible.

Availability of data and computing code
=======================================

The analytic code is available at <https://github.com/pcornet-analytics/bariatric>.
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![Computation process of a typical regression analysis.\
**Note:** Numbers are hypothetical and for demonstrative purposes only.\
**Abbreviations:** SSCP, sums of squares and cross products; SE, standard error.](clep-10-1773Fig1){#f1-clep-10-1773}

![Distributed regression in a multicenter study.\
**Note:** Numbers are hypothetical and for demonstrative purposes only.\
**Abbreviation:** SSCP, sums of squares and cross products.](clep-10-1773Fig2){#f2-clep-10-1773}
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###### 

Baseline characteristics of patients who underwent Roux-en-Y gastric bypass or sleeve gastrectomy procedure from 36 health systems participating in the PCORnet Bariatric Study

  Variable[a](#tfn1-clep-10-1773){ref-type="table-fn"}                          Roux-en-Y gastric bypass   Sleeve gastrectomy            
  ----------------------------------------------------------------------------- -------------------------- -------------------- -------- -------
                                                                                                                                         
  Total                                                                         23,963                     100.0                19,147   100.0
  Age                                                                                                                                    
   20--44                                                                       11,059                     46.2                 9,547    49.9
   45--64                                                                       11,728                     48.9                 8,648    45.2
   65--80                                                                       1,176                      4.9                  952      5.0
  Male sex                                                                      4,701                      19.6                 3,748    19.6
  Race                                                                                                                                   
   White                                                                        16,995                     70.8                 10,970   57.3
   Black                                                                        3,468                      14.5                 4,618    24.1
   Other                                                                        3,540                      14.8                 3,559    18.6
  Hispanic ethnicity                                                            3,813                      15.9                 4,624    24.2
  Year of procedure                                                                                                                      
   2005--2009                                                                   1,937                      8.1                  424      2.2
   2010                                                                         3,487                      14.6                 1,195    6.2
   2011                                                                         4,767                      19.9                 3,138    16.4
   2012                                                                         6,101                      25.5                 4,011    21.0
   2013                                                                         3,850                      16.1                 4,771    24.9
   2014                                                                         3,315                      13.9                 4,908    25.6
   2015                                                                         506                        2.1                  700      3.7
   Comorbidity score (SD)                                                       −0.01                      0.9                  −0.04    0.9
   Baseline weight (SD)                                                         280.37                     57.0                 274.86   57.6
   Baseline weight proximity[b](#tfn2-clep-10-1773){ref-type="table-fn"} (SD)   −21.64                     35.3                 −14.60   31.2
   Days of hospitalization (SD)                                                 0.60                       8.0                  0.49     6.6
   Smoking                                                                      2,278                      9.5                  1,605    8.4
  Diagnosis of                                                                                                                           
   Anxiety                                                                      5,404                      22.6                 4,080    21.3
   Deep vein thrombosis                                                         181                        0.8                  150      0.8
   Depression                                                                   8,150                      34.0                 5,540    28.9
   Diabetes                                                                     10,608                     44.3                 5,677    29.7
   Dyslipidemia                                                                 12,663                     52.8                 8,868    46.3
   Eating disorder                                                              3,833                      16.0                 1,168    6.1
   GERD                                                                         11,196                     46.7                 6,917    36.1
   Hypertension                                                                 15,452                     64.5                 10,798   56.4
   Infertility                                                                  172                        0.7                  159      0.8
   Kidney disease                                                               2,172                      9.1                  1,469    8.0
   NAFLD                                                                        6,853                      28.6                 3,231    16.9
   Osteoarthritis                                                               461                        1.9                  337      1.8
   PCOS                                                                         1,281                      5.4                  919      4.8
   Psychosis                                                                    1,240                      5.2                  701      3.7
   Pulmonary embolism                                                           320                        1.3                  225      1.2
   Sleep apnea                                                                  13,116                     54.7                 8,255    43.1
   Substance use disorder                                                       522                        2.2                  462      2.4

**Notes:**

Measured in the year prior to the surgery unless otherwise specified;

number of days between baseline weight measurement and index procedure.

**Abbreviations:** GERD, gastroesophageal reflux disease; NAFLD, nonalcoholic fatty liver disease; PCORnet, National Patient-Centered Clinical Research Network; PCOS, polycystic ovarian syndrome.

###### 

Results from a linear regression model that adjusted for sites and confounders as individual covariates (Model 1) from 36 health systems participating in the PCORnet Bariatric Study

  Variable[a](#tfn4-clep-10-1773){ref-type="table-fn"}                                                                  Parameter estimate   SE                         
  --------------------------------------------------------------------------------------------------------------------- -------------------- ------------- ------------ ------------
                                                                                                                                                                        
  Exposure[b](#tfn5-clep-10-1773){ref-type="table-fn"}                                                                  −0.05312             −0.05312      0.00105      0.00105
  Age                                                                                                                                                                   
   20--44                                                                                                               −0.01662             −0.01662      0.00106      0.00106
   45--64                                                                                                               Reference            Reference     Reference    Reference
   65--80                                                                                                               0.01339              0.01339       0.00218      0.00218
  Male sex                                                                                                              0.02162              0.02162       0.00133      0.00133
  Race                                                                                                                                                                  
   White                                                                                                                Reference            Reference     Reference    Reference
   Black                                                                                                                0.02873              0.02873       0.00130      0.00130
   Other                                                                                                                0.00883              0.00883       0.00153      0.00153
  Hispanic ethnicity                                                                                                    0.00227              0.00227       0.00147      0.00147
  Year of procedure                                                                                                                                                     
   2005--2009                                                                                                           −0.00319             −0.00319      0.00218      0.00218
   2010                                                                                                                 −0.00301             −0.00301      0.00169      0.00169
   2011                                                                                                                 −0.00326             −0.00326      0.00144      0.00144
   2012                                                                                                                 Reference            Reference     Reference    Reference
   2013                                                                                                                 0.00384              0.00384       0.00141      0.00141
   2014                                                                                                                 0.00569              0.00569       0.00145      0.00145
   2015                                                                                                                 0.03664              0.03664       0.00288      0.00288
   Comorbidity score[c](#tfn6-clep-10-1773){ref-type="table-fn"},[d](#tfn7-clep-10-1773){ref-type="table-fn"}           0.00576              0.00576       0.00069243   0.00069243
   Baseline weight[c](#tfn6-clep-10-1773){ref-type="table-fn"},[d](#tfn7-clep-10-1773){ref-type="table-fn"}             −0.00025096          −0.00025096   0.00000921   0.00000921
   Baseline weight proximity[d](#tfn7-clep-10-1773){ref-type="table-fn"},[e](#tfn8-clep-10-1773){ref-type="table-fn"}   0.00012330           0.00012330    0.00001430   0.00001430
   Smoking[c](#tfn6-clep-10-1773){ref-type="table-fn"}                                                                  −0.00657             −0.00657      0.00163      0.00163
   Days of hospitalization[c](#tfn6-clep-10-1773){ref-type="table-fn"},[d](#tfn7-clep-10-1773){ref-type="table-fn"}     0.00017944           0.00017944    0.00006129   0.00006129
  Diagnosis of[c](#tfn6-clep-10-1773){ref-type="table-fn"}                                                                                                              
   Anxiety                                                                                                              0.00036721           0.00036721    0.00119      0.00119
   Deep vein thrombosis                                                                                                 0.00245              0.00245       0.00530      0.00530
   Depression                                                                                                           0.00412              0.00412       0.00107      0.00107
   Diabetes                                                                                                             0.01914              0.01914       0.00107      0.00107
   Dyslipidemia                                                                                                         0.00169              0.00169       0.00103      0.00103
   Eating disorder                                                                                                      −0.00247             −0.00247      0.00236      0.00236
   GERD                                                                                                                 −0.00132             −0.00132      0.00095329   0.00095329
   Hypertension                                                                                                         0.01454              0.01454       0.00124      0.00124
   Infertility                                                                                                          0.00842              0.00842       0.00521      0.00521
   Kidney disease                                                                                                       0.00059350           0.00059350    0.00176      0.00176
   NAFLD                                                                                                                −0.00652             −0.00652      0.00150      0.00150
   Osteoarthritis                                                                                                       −0.00253             −0.00253      0.00337      0.00337
   PCOS                                                                                                                 0.00118              0.00118       0.00212      0.00212
   Psychosis                                                                                                            0.00006296           0.00006296    0.00226      0.00226
   Pulmonary embolism                                                                                                   0.00722              0.00722       0.00414      0.00414
   Sleep apnea                                                                                                          −0.00153             −0.00153      0.00098117   0.00098117
   Substance use disorder                                                                                               −0.00729             −0.00729      0.00310      0.00310

**Notes:**

Also adjusted for sites (35 indicator variables; results not shown for brevity);

Roux-en-Y gastric bypass vs sleeve gastrectomy;

measured in the year prior to the surgery;

modeled as a continuous variable;

number of days between baseline weight measurement and index procedure.

**Abbreviations:** GERD, gastroesophageal reflux disease; NAFLD, nonalcoholic fatty liver disease; PCORnet, National Patient-Centered Clinical Research Network; PCOS, polycystic ovarian syndrome; SE, standard error.

###### 

Results from a linear regression model that adjusted for sites and confounders as propensity score deciles (Model 2) from 36 health systems participating in the PCORnet Bariatric Study

  Variable[a](#tfn10-clep-10-1773){ref-type="table-fn"}   Parameter estimate   SE                       
  ------------------------------------------------------- -------------------- ------------ ----------- -----------
                                                                                                        
  Exposure[b](#tfn11-clep-10-1773){ref-type="table-fn"}   −0.05470             −0.05470     0.00113     0.00113
  PS stratum 1                                            Reference            Reference    Reference   Reference
  PS stratum 2                                            −0.00754             −0.00754     0.00209     0.00209
  PS stratum 3                                            −0.00671             −0.00671     0.00210     0.00210
  PS stratum 4                                            −0.00717             −0.00717     0.00211     0.00211
  PS stratum 5                                            0.00034218           0.00034218   0.00212     0.00212
  PS stratum 6                                            −0.00583             −0.00583     0.00213     0.00213
  PS stratum 7                                            −0.00135             −0.00135     0.00214     0.00214
  PS stratum 8                                            −0.00435             −0.00435     0.00216     0.00216
  PS stratum 9                                            −0.00523             −0.00523     0.00218     0.00218
  PS stratum 10                                           −0.00812             −0.00812     0.00222     0.00222

**Notes:**

Also adjusted for sites (35 indicator variables; results not shown for brevity);

Roux-en-Y gastric bypass vs sleeve gastrectomy.

**Abbreviations:** PCORnet, National Patient-Centered Clinical Research Network; PS, propensity score; SE, standard error.

###### 

Results from a linear regression model that adjusted for sites and confounders as both individual covariates and propensity score deciles (Model 3) from 36 health systems participating in the PCORnet Bariatric Study

  Variable[a](#tfn13-clep-10-1773){ref-type="table-fn"}                                                                  Parameter estimate   SE                         
  ---------------------------------------------------------------------------------------------------------------------- -------------------- ------------- ------------ ------------
                                                                                                                                                                         
  Exposure[b](#tfn14-clep-10-1773){ref-type="table-fn"}                                                                  −0.05355             −0.05355      0.00108      0.00108
  Age                                                                                                                                                                    
   20--44                                                                                                                −0.01668             −0.01668      0.00106      0.00106
   45--64                                                                                                                Reference            Reference     Reference    Reference
   65--80                                                                                                                0.01364              0.01364       0.00218      0.00218
  Male sex                                                                                                               0.02189              0.02189       0.00134      0.00134
  Race                                                                                                                                                                   
   White                                                                                                                 Reference            Reference     Reference    Reference
   Black                                                                                                                 0.02917              0.02917       0.00132      0.00132
   Other                                                                                                                 0.00877              0.00877       0.00153      0.00153
  Hispanic ethnicity                                                                                                     0.00218              0.00218       0.00148      0.00148
  Year of procedure                                                                                                                                                      
   2005--2009                                                                                                            −0.00372             −0.00372      0.00241      0.00241
   2010                                                                                                                  −0.00352             −0.00352      0.00187      0.00187
   2011                                                                                                                  −0.00348             −0.00348      0.00146      0.00146
   2012                                                                                                                  Reference            Reference     Reference    Reference
   2013                                                                                                                  0.00453              0.00453       0.00146      0.00146
   2014                                                                                                                  0.00683              0.00683       0.00157      0.00157
   2015                                                                                                                  0.03793              0.03793       0.00295      0.00295
  Comorbidity score[c](#tfn15-clep-10-1773){ref-type="table-fn"},[d](#tfn16-clep-10-1773){ref-type="table-fn"}           0.00585              0.00585       0.00069368   0.00069368
  Baseline weight[c](#tfn15-clep-10-1773){ref-type="table-fn"},[d](#tfn16-clep-10-1773){ref-type="table-fn"}             −0.00025150          −0.00025150   0.00000922   0.00000922
  Baseline weight proximity[d](#tfn16-clep-10-1773){ref-type="table-fn"},[e](#tfn17-clep-10-1773){ref-type="table-fn"}   0.00012628           0.00012628    0.00001507   0.00001507
  Smoking[c](#tfn15-clep-10-1773){ref-type="table-fn"}                                                                   −0.00653             −0.00653      0.00163      0.00163
  Days of hospitalization[c](#tfn15-clep-10-1773){ref-type="table-fn"},[d](#tfn16-clep-10-1773){ref-type="table-fn"}     0.00018276           0.00018276    0.00006130   0.00006130
  Diagnosis of[c](#tfn15-clep-10-1773){ref-type="table-fn"}                                                                                                              
   Anxiety                                                                                                               0.00040061           0.00040061    0.00119      0.00119
   Deep vein thrombosis                                                                                                  0.00272              0.00272       0.00530      0.00530
   Depression                                                                                                            0.00403              0.00403       0.00107      0.00107
   Diabetes                                                                                                              0.01859              0.01859       0.00115      0.00115
   Dyslipidemia                                                                                                          0.00164              0.00164       0.00103      0.00103
   Eating disorder                                                                                                       −0.00226             −0.00226      0.00236      0.00236
   GERD                                                                                                                  −0.00164             −0.00164      0.00097208   0.00097208
   Hypertension                                                                                                          0.01451              0.01451       0.00124      0.00124
   Infertility                                                                                                           0.00880              0.00880       0.00521      0.00521
   Kidney disease                                                                                                        0.00055973           0.00055973    0.00176      0.00176
   NAFLD                                                                                                                 −0.00680             −0.00680      0.00150      0.00150
   Osteoarthritis                                                                                                        −0.00244             −0.00244      0.00337      0.00337
   PCOS                                                                                                                  0.00127              0.00127       0.00212      0.00212
   Psychosis                                                                                                             0.00003263           0.00003263    0.00226      0.00226
   Pulmonary embolism                                                                                                    0.00757              0.00757       0.00415      0.00415
   Sleep apnea                                                                                                           −0.00177             −0.00177      0.00098965   0.00098965
   Substance use disorder                                                                                                −0.00745             −0.00745      0.00310      0.00310
  PS stratum 1                                                                                                           Reference            Reference     Reference    Reference
  PS stratum 2                                                                                                           0.00180              0.00180       0.00204      0.00204
  PS stratum 3                                                                                                           0.00362              0.00362       0.00207      0.00207
  PS stratum 4                                                                                                           0.00058495           0.00058495    0.00211      0.00211
  PS stratum 5                                                                                                           0.00731              0.00731       0.00217      0.00217
  PS stratum 6                                                                                                           0.00056111           0.00056111    0.00223      0.00223
  PS stratum 7                                                                                                           0.00508              0.00508       0.00231      0.00231
  PS stratum 8                                                                                                           0.00383              0.00383       0.00242      0.00242
  PS stratum 9                                                                                                           0.00516              0.00516       0.00257      0.00257
  PS stratum 10                                                                                                          0.00336              0.00336       0.00285      0.00285

**Notes:**

Also adjusted for sites (35 indicator variables; results not shown for brevity);

Roux-en-Y gastric bypass vs sleeve gastrectomy;

measured in the year prior to the surgery;

modeled as a continuous variable;

number of days between baseline weight measurement and index procedure.

**Abbreviations:** GERD, gastroesophageal reflux disease; NAFLD, nonalcoholic fatty liver disease; PCORnet, National Patient-Centered Clinical Research Network; PCOS, polycystic ovarian syndrome; PS, propensity score; SE, standard error.
